Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Arena and Taisho expand obesity orphan receptor research agreement

Feb. 1, 2001

Two new series of vitronectin receptor antagonists particularly useful in osteoporosis

Feb. 1, 2001

Testosterone progressive hydration buccal tablets show promise in phase III

Feb. 1, 2001

PK/PD modeling following single oral doses of NN-703

Feb. 1, 2001

OP-1 receives positive and negative opinions from regulatory authorities

Feb. 1, 2001

Oxagen and Incyte partner for gene-based osteoporosis research

Jan. 31, 2001

Starlix, the first in a new class of agents for type 2 diabetes, recommended for E.U. approval

Jan. 30, 2001

Bone-stimulating factors under evaluation at Osteopharm

Jan. 26, 2001

Studies explore mechanism of glucose-dependent insulinotropic effects of JTT-608

Jan. 26, 2001

Actos may now be prescribed in U.K. for the management of type 2 diabetes

Jan. 26, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...